title: Combination of injectable ethinyl estradiol and drospirenone drug-delivery systems and characterization of their in vitro release.
abstract: Our aim was to investigate the in vitro release and combination of ethinyl estradiol (EE) and drospirenone (DRSP) drug-delivery systems. DRSP poly(lactic-co-glycolic acid) (PLGA) microparticles and organogels containing DRSP microcrystals were prepared and characterized with regard to properties influencing drug release. The morphology and release kinetics of DRSP PLGA microparticles indicated that DRSP is dispersed in the polymer. The in vitro release profiles correlated well with in vivo data. Although DRSP degradation is known to be acid-catalyzed, DRSP was relatively stable in the PLGA matrix. Aqueous DRSP PLGA microparticle suspensions were combinable with EE PLGA microparticles and EE poly(butylcyanoacrylate) (PBCA) microcapsules without interacting. EE release from PLGA microparticles was faster than DRSP release; EE release is assumed to be primarily controlled by drug diffusion. Liquid-filled EE PBCA microcapsules were shown to be more robust than air-filled EE PBCA microcapsules; the bursting of microcapsules accelerating the drug delivery was therefore delayed. The drug release profile for DRSP organogels was fairly linear with the square root of time. The system was not combinable with EE PBCA microcapsules. In contrast, incorporation of EE PLGA microparticles in organogels resulted in prolonged EE release. The drug release of EE and DRSP was thus approximated.
authors.affiliation: Pharmaceutical Technology, Bayer HealthCare Pharmaceuticals, Muellerstr. 170, 13342 Berlin, Germany. stefanie.nippe@googlemail.com
authors.forename: Stefanie
authors.initials: S
authors.lastname: Nippe
authors.forename: Sascha
authors.initials: S
authors.lastname: General
mesh_terms: D000736:Androstenes / Q000008:administration & dosage / Q000737:chemistry*; D002214:Capsules / Q000008:administration & dosage / Q000737:chemistry*; D003487:Cyanoacrylates / Q000008:administration & dosage / Q000737:chemistry; D016503:Drug Delivery Systems / Q000379:methods*; D004659:Enbucrilate; D004997:Ethinyl Estradiol / Q000008:administration & dosage / Q000737:chemistry*; D007267:Injections / Q000379:methods; D007700:Kinetics; D019344:Lactic Acid / Q000008:administration & dosage / Q000737:chemistry; D010316:Particle Size; D011100:Polyglycolic Acid / Q000008:administration & dosage / Q000737:chemistry; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000737:chemistry; D013535:Suspensions / Q000008:administration & dosage* / Q000737:chemistry
chemical_list: D000736:Androstenes; D002214:Capsules; D003487:Cyanoacrylates; D011108:Polymers; D013535:Suspensions; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D004997:Ethinyl Estradiol; D004659:Enbucrilate; C035144:drospirenone